

1 **COVID-19 in Pakistan: A national analysis of five pandemic waves**

2 **Short title: COVID-19 waves in Pakistan**

3

4 Taimoor Ahmad¹, Mujahid Abdullah¹, Abdul Mueed¹, Faisal Sultan^{2,3}, Ayesha Khan¹,
5 Adnan Ahmad Khan^{2,4*}

6

7 ¹Akhter Hameed Khan Foundation, Islamabad, Pakistan

8 ²Ministry of National Health Services, Regulation and Coordination, Islamabad, Pakistan

9 ³Shaukat Khanum Memorial Cancer Hospital & Research Centre, Lahore, Pakistan

10 ⁴Research and Development Solutions, Islamabad, Pakistan

11

12 ***Corresponding Author**

13 Email: adnan@resdev.org

14 **Disclosures:**

15 This work was supported, in whole or in part, by the Bill & Melinda Gates Foundation
16 [grant number: INV-025171]. Under the grant conditions of the Foundation, a Creative
17 Commons Attribution 4.0 Generic License has already been assigned to the Author
18 Accepted Manuscript version that might arise from this submission.

19

20

21

22

23

24

25 **ABSTRACT**

26 **Objectives**

27 The COVID-19 pandemic showed distinct waves where cases ebbed and flowed. While
28 each country had slight, nuanced differences, lessons from each wave with country-
29 specific details provides important lessons for prevention, understanding medical
30 outcomes and the role of vaccines. This paper compares key characteristics from the five
31 different COVID-19 waves in Pakistan.

32 **Methods**

33 We used specific criteria to define COVID-19 waves, and key variables such as COVID-
34 19 tests, cases, and deaths with their rates of change to the peak and then to the trough
35 were used to draw descriptive comparisons. Additionally, a linear regression model
36 estimated daily new COVID-19 deaths in Pakistan.

37 **Results**

38 Pakistan saw five distinct waves, each of which displayed the typical topology of a
39 complete infectious disease epidemic. The time from wave-start to peak became
40 progressively shorter, and from wave-peak to trough, progressively longer. Each wave
41 appears to also be getting shorter, except for wave 4, which lasted longer than wave 3. A
42 one percent increase in vaccinations increased daily new COVID-19 deaths by 0.10%
43 (95% CI: 0.01, 0.20) in wave 4 and decreased deaths by 0.38% (95% CI: -0.67, -0.08) in
44 wave 5.

45 **Conclusion**

46 Each wave displayed distinct characteristics that must be interpreted in the context of the
47 level of response and the variant driving the epidemic. Key indicators suggest that
48 COVID-19 preventive measures kept pace with the disease. Waves 1 and 2 were mainly
49 about prevention and learning how to clinically manage patients. Vaccination started late
50 during Wave 3 and its impact became apparent on hospitalizations and deaths in Wave
51 5. The impact of highly virulent strains Alpha/B.1.1.7 and Delta/B.1.617.2 variants during
52 Wave 3 and milder but more infectious Omicron/BA.5.2.1.7 are apparent.

53 **INTRODUCTION**

54 In Pakistan, the first case of COVID-19, a novel and little-understood disease, was
55 detected on February 26, 2020. Being a developing country with limited resources,
56 crumbling health infrastructure and low health expenditure (1), Pakistan has no past
57 experience with pandemics and a high burden of communicable diseases (2). As of
58 February 23, 2022, the country had fully vaccinated 43% of its total population (3) and the
59 Omicron variant of COVID-19 was the dominant strain (4). These factors make Pakistan
60 a high-risk country, with a large pool of infection-susceptible people.

61 The emergence of COVID-19 has arguably been the biggest social and economic
62 disruption in Pakistan in recent history. The pandemic has largely manifested itself in five
63 distinct waves each of which have a rise, plateau and trough in cases, followed by a
64 period of dormancy, after which the incidence of COVID-19 infections begins to rise again.
65 Thus, each individual wave follows a four stage pattern followed by endemicity that has
66 been seen for many infectious disease epidemics (12). Beyond anecdotal observation,
67 there is evidence that this is happening with COVID-19 as well (11). What sets COVID-

68 19 apart is that after completion of an individual wave, a new one would come along
69 shortly, rather than much long, for example, annual, recurrences for influenza etc. This
70 pattern has been seen all across the globe (5–10) with the timing of COVID-19 waves in
71 different countries broadly coinciding (11).

72 In this context, current literature on COVID-19 largely focuses on high-income countries
73 during the initial waves (2,13–17), or aggregated at a regional level (5,6). Given the
74 different capacities of countries to manage the pandemic (17), there is a need to explore
75 the characteristics of the subsequent pandemic waves in a developing country context,
76 preferably with granularity of a country-level analysis (2,13–17).

77 To this end, this paper explores how each of the five waves of the COVID-19 pandemic
78 in Pakistan differed from each other in terms of the total duration of each wave, the time
79 from the start of each wave to its peak, and from its peak to the wave's trough; the length
80 of time in between each wave; as well as key descriptive features like the total number of
81 COVID-19 tests, COVID-19 cases, hospitalizations, deaths from COVID-19, and COVID-
82 19 vaccinations in each wave. Additionally, this study statistically models the key factors
83 that lead to deaths from COVID-19.

84 **METHODS**

85 **Criteria for COVID-19 waves**

86 We begin by retrospectively defining various time periods between 2020 and 2022 as
87 distinct waves, based on existing literature (18). There are a total of 628 observations
88 (daily set of indicators) across these five waves. Based on our criteria, the starting point
89 of each COVID-19 wave is defined as the day with the lowest number of daily new COVID-

90 19 cases preceding a consistent rise in these cases, before the peak of the respective
91 COVID-19 wave. The end of each wave is defined as the day with lowest number of daily
92 new COVID-19 cases following a 7-day decline; this number also needed to be lower than
93 the cases on any of the 7 days that followed it (Table 1).

94 **Data and variables**

95 In order to estimate the pattern for COVID-19 throughout the five waves in Pakistan, we
96 have used time series of various daily indicators from April 3, 2020 to February 23, 2022,
97 which categorized into following themes:

- 98 i) Wave timespan
- 99 ii) COVID-19 tests
- 100 iii) COVID-19 cases
- 101 iv) Test-to-case ratio
- 102 v) COVID-19 positivity
- 103 vi) Hospitalization, treatment, and containment
- 104 vii) COVID-19 deaths
- 105 viii) COVID-19 vaccination
- 106 ix) Policy environment

107 Several variables in the list above were transformed into ratios for the purpose of
108 describing all five COVID-19 waves in Pakistan (Supplementary Table S1).

109 The data for all but two of the above variables, second doses of COVID-19 vaccines
110 administered and the Oxford Containment and Health Index for COVID-19, was compiled
111 from daily national situation reports (Sitreps). These Sitreps are prepared by the National

112 Emergency Operations Centre (NEOC) in Islamabad, Pakistan. Data in these Sitreps
113 have served as the basis for all major COVID-19 policy decisions in Pakistan.

114 The data for second doses of COVID-19 vaccines administered was sourced directly from
115 the National Command & Operation Centre (NCOC), Islamabad, Pakistan, which is the
116 government forum that brings together the ministries of Health and Planning along with
117 the military to determine pandemic policy and to coordinate the response. Data for the
118 Oxford Containment and Health Index is taken from a publicly available dataset from the
119 University of Oxford's Blavatnik School of Governance (19). This dataset is compiled by
120 using qualitative information about the non-pharmaceutical interventions (NPIs) in a
121 country and quantifying them into an index. A detailed methodology of the index
122 calculation can be found in a working paper by the Blavatnik school (20).

123 **Model Specification**

124 For our model for COVID-19 deaths, we used a linear ordinary least square (OLS)
125 regression carried out using STATA 17. The data as well as the model was divided into
126 five distinct periods, representing the five waves of COVID-19 in Pakistan, as of February
127 2022. Regression analysis was performed separately on each wave and results were
128 compared with each other to make logical inferences.

129 Our dependent variable is the Daily New COVID-19 Deaths in Pakistan in logarithmic
130 form ($\text{Ln}Y_t$); ϵ_t represents the error term capturing the effect of omitted variables. The
131 specification of our linear OLS regression model is as following:

$$132 \quad \text{Ln} Y_t = \beta_0 + \beta_1 \text{Ln} X_{1t} + \beta_2 \text{Ln} X_{2t} + \beta_3 X_{3t} + \beta_4 X_{4t} + \beta_5 X_{5t} + \beta_6 X_{6t} + \beta_7 \text{Ln} X_{7t} + \epsilon_t$$

133 We have chosen seven independent variables:

- 134 i) Log of daily new COVID-19 cases with 21-day delay (LnX_{1t});
- 135 ii) Log of daily new COVID-19 tests with 28-day delay (LnX_{2t});
- 136 iii) The Oxford Containment and Health Index for COVID-19 with 14-day delay (X_{3t});
- 137 iv) Time (X_{4t});
- 138 v) The number of people on ventilators as a proportion of the total admitted (X_{5t});
- 139 vi) The number of people on oxygen as a portion of the total admitted (X_{6t});
- 140 vii) Log of second doses of COVID-19 vaccines administered with 14- day delay (
141 LnX_{7t})

142 Daily new COVID-19 cases were regressed with a 21-day lag, since among those who
143 die from COVID-19 infection, death occurs between a median of 14 days (21) and 25
144 days (average of three weeks) after presenting symptoms (22,23). This is pertinent in the
145 case of Pakistan, as most of the COVID-19 testing in the country has been symptomatic,
146 i.e., done when someone develops symptoms of COVID-19 and hence either voluntarily
147 gets tested or is prescribed by a medical professional to do so.

148 Given the delay for daily new cases, daily new COVID-19 tests were regressed with a
149 delay of 28 days. This delay allows for the time it takes for someone to test positive for
150 COVID-19 and for their symptoms to worsen (for example, by escalating to
151 hospitalization, which takes nearly a week (24) before resulting in death. For vaccination,
152 a 14-day lag was taken, as immunity from vaccines is generally understood to develop
153 two weeks or longer after receiving a shot (25–27).

154 The Oxford Containment and Health Index is calculated out of 100 which means strict
155 restrictions and a lower value indicate a smaller number of restrictions imposed on the

156 general population. This variable was regressed with a 14-day lag, as we assume that
157 any new government restrictions will take approximately that long to have any effect.
158 Additionally, the time variable is meant to capture any unmeasured or seasonal effects
159 on COVID-19 deaths in Pakistan, such as an overall rate of increase/ decrease of daily
160 deaths in each wave. We assume the error term is not correlated with any of the
161 independent variable.

162 Diagnostic tests were performed on the estimated model to ensure the precision of the
163 estimated coefficient: for heteroskedasticity, the Breusch-Pagan test was applied,
164 whereas for serial correlation, the Durbin-Watson test was used. Variance inflation factor
165 (VIF) was calculated for multicollinearity. Dickey-Fuller tests were run for each
166 independent variable in our regression model. All of the variables were found to be
167 stationary, fulfilling an important pre-requisite for our analysis (Table 1).

168 **Table 1. Augmented Dicky-Fuller tests for unit roots**

Variable	Test Statistics	P-Value	H ₀ : Random Walk
Daily New COVID-19 Deaths	-6.96	0.000	Stationary
Daily New COVID-19 Cases	-3.23	0.018	Stationary
Daily New COVID-19 Tests	-3.94	0.0017	Stationary
Oxford Containment and Health Index	-3.30	0.015	Stationary
Ventilator-admitted Ratio	-5.69	0.000	Stationary
Oxygen-Admitted Ratio	-3.00	0.034	Stationary
Fully Vaccinated People	-2.77	0.003	Stationary

169

170 RESULTS

171 Summary statistics

172 Pakistan experienced five distinct waves from 3rd April 2020 till 23rd February 2022 (Fig
173 1). The first wave lasted the longest (150 days), while the fifth one was the shortest (83

174 days). The fourth wave was remarkable for its relatively rapid upslope and a long tail,
 175 while the fifth wave showed the reverse pattern. The duration of each wave of COVID-19
 176 in Pakistan was shorter than the preceding one apart from wave 4. After wave 1, each
 177 wave took less time to reach its peak and took longer to reach its trough apart from wave
 178 5.

179 **Figure 1. COVID-19 waves and daily new cases**

180 The capacity to conduct tests expanded over time from an average of 17,142 tests daily
 181 during the first wave to 49,650 during fifth wave. The increase in the daily tests peaked
 182 during the fourth wave. The highest average daily number of cases (3147) were observed
 183 during the wave 3. The rate of increase of COVID-19 cases was highest during wave 4,
 184 but the rate of decline in cases after the peak of a wave was fastest during wave 5. Test
 185 to case ratio kept on increasing from 15 during the first wave to 57 during the fifth one.
 186 While total positivity varied across waves, the rate in daily change of positivity remained
 187 relatively unchanged apart from wave 2 and 3, where it is lower as compared to other
 188 waves (Table 2).

189 **Table 2. Descriptive characteristics of each COVID-19 wave**

Variables	Wave 1	Wave 2	Wave 3	Wave 4	Wave 5
Dates	April 3, 2020 to August 31, 2020	October 12, 2020 to February 16, 2021	February 23, 2021 to June 22, 2021	July 6, 2021 to November 29, 2021	December 7, 2021 to February 23, 2022
Main Variants of Concern (VOCs)	B.1	B.1.36	Alpha/ B1.1.7/ Delta/B.1.617.2	Delta/B.1.617.2	Omicron/BA.5.2.1.7
Timespan					
Duration of wave (days)	150	128	120	147	83
From wave Start till Peak (days)	72	57	55	31	52
From wave Peak till Trough (days)	78	71	65	116	31
COVID-19 Tests					

Total tests in the entire wave		2,571,244	4,638,219	5,458,041	7,148,130	4,120,909
Avg. Daily New COVID-19 Tests		17,142 (7,931)	36,236 (5,363)	45,484 (8,623)	48,627 (8341)	49,650 (7494)
Rate of Change of Daily New Tests	Up to Peak	380.9	216.5	701.1	836.6	540.4
Rate of Change of Daily New Tests	After Peak	-147.8	-101.0	-504.9	-286.4	-1137.6
COVID-19 Cases						
Total cases in the entire wave		293,752	246,188	377,668	320,333	221,825
Avg. Daily New COVID-19 Cases		1,958 (1,687)	1,923 (815)	3,147 (1,547)	2,179 (1548)	2,673 (2519)
Rate of Change of Daily New Cases	Up to Peak	93.9	60.9	94.0	161.0	155.9
Rate of Change of Daily New Cases	After Peak	-84.8	-40.0	-84.1	-48.0	-236.4
Test-to-Case Ratio						
Average Test-to-Case Ratio		15 (15)	23 (11)	19 (11)	44 (38)	57 (56)
Rate of Change of Test-to-Case Ratio	Up to Peak	4.1	-1.1	-0.4	-1.13	-3.31
Rate of Change of Test-to-Case Ratio	After Peak	84.5	0.3	0.7	1.36	0.99
COVID-19 Positivity						
Avg. Daily Positivity Ratio during the wave		11.3% (6.4%)	5.2% (1.8%)	6.8% (2.9%)	4.2% (2.6%)	4.9% (4.1%)
Rate of Change of Positivity Ratio	Up to Peak	0.23	0.15	0.10	0.23	0.22
Rate of Change of Positivity Ratio	After Peak	-0.28	-0.10	-0.11	-0.07	-0.30
Hospitalization, Treatment, and Containment						
Avg. COVID-19 Hospital Admissions at any given time		3,817 (2,479)	2,187 (818)	3,970 (1,366)	3,396 (1,776)	1125 (423)
Avg. Length of Hospital Stay (days) ^a		-	13	11	9	5
Avg. Daily New Hospitalization to Daily New Case Ratio (%)		-	8.8 (2.4)	12.4 (3.5)	22.7 (10.7)	15.7 (10.8)
Avg. Daily Recoveries and Hospital Discharges		1,870 (2,587)	1,746 (1,608)	2,990 (1,454)	2,272 (2,329)	2371 (3797)
Rate of Change of Daily Recoveries and Hospital Discharges (non-cumulative)	Up to Peak	23.4	14.3	69.9	202.4	28.76

Rate of Change of Daily Recoveries and Hospital Discharges (non-cumulative)	After Peak	-19.8	-6.6	-51.1	-57.7	-0.97
Avg. Stable-Admitted Ratio (%)		67% (27%)	20% (6%)	14% (5%)	7% (4%)	9% (4%)
Avg. Patients on Oxygen-Admitted Ratio (%)		27% (23%)	68% (5%)	75% (5%)	83% (2%)	81% (3%)
Avg. Number of Oxygen Beds in Use at any given time		865 (828)	1,521 (608)	2,995 (1,080)	2,803 (1,470)	918 (361)
Avg. Oxygen Beds Utilization Ratio (%)		18% (11%)	15% (6%)	24% (8%)	20% (10%)	7% (3%)
Avg. Number of Ventilators in Use at any given time		214 (163)	249 (90)	429 (145)	336 (153)	109 (36)
Avg. Ventilator-Admission Ratio (%)		7% (4%)	11% (1%)	11% (0.6%)	10% (2%)	10% (1%)
Avg. Ventilators Utilization Ratio (%)		17% (10%)	13% (5%)	20% (7%)	15% (7%)	5% (2%)
COVID-19 Deaths						
Total COVID-19 deaths in the entire wave		6,204	5,537	9,423	6,287	1,401
Avg. Daily New COVID-19 Deaths		41.4 (35.3)	43.3 (23.0)	78.5 (37.4)	42.8 (30.6)	16.9 (14.3)
Rate of Change of Daily New COVID-19 Deaths	Up to Peak	1.1	0.5	2.0	1.17	0.45
Rate of Change of Daily New COVID-19 Deaths	After Peak	-1.0	0.1	-1.9	-0.44	-0.81
Avg. Daily New COVID-19 Deaths - Daily Hospitalization Ratio (%)		11% (5%)	27% (13%)	23% (8%)	10% (4%)	7% (4%)
Avg. Daily New COVID-19 Deaths – Ventilator in use Ratio (%)		23% (17%)	17% (6%)	18% (5%)	12% (5%)	13% (8%)
Avg. Death-to-Case Ratio (%)		2.2% (0.8%)	2.3% (1.1%)	2.8% (1.2%)	2.2% (0.8%)	1.1% (1.0%)
COVID-19 Vaccination^b						
Total Administration of 2 nd doses of Vaccine		-	-	3,136,386	45,294,948	45,667,572
Avg. Daily New Administration of 2 nd doses of Vaccine		-	-	26,356 (25,980)	308,129 (172,896)	550,212 (186,287)
Policy Environment						
Oxford Containment and Health Index		58.8 (7.6)	62.4 (4.0)	65.7 (6.3)	58.1 (9.4)	58.6 (5.5)

190 *Standard deviations are reported in parentheses.*

191 ^aData for daily new COVID-19 hospitalizations was not available during wave 1.

192 ^bCOVID-19 vaccines were not being administered during waves 1 and 2.

193

194 Hospitalizations were the highest for the first and the third wave and the least for the fifth,
195 whereas duration of hospitalization fell linearly from an initial 13 days during the second
196 wave to 5 days during the fifth. Hospitalizations became more specific over time in that,
197 nearly two third of admitted patients during the first wave were stable, compared to 9%
198 during the fifth one. The average stable-admitted ratio decreased continuously from wave
199 1 to wave 4 but increased slightly in wave 5. The rate at which people recovered from
200 COVID-19 and/or were discharged from hospital was highest in wave 4 and slowest in
201 wave 2.

202 The average Oxygen Beds-Admitted Ratio continuously increasing in each wave,
203 reaching its maximum value in wave 4. During the first wave 27% of all admissions
204 required oxygen, 7% needed a ventilator, compared to 81% and 10% respectively during
205 the fifth wave. The average oxygen bed utilization followed a declining trend except for
206 the third wave (24%) and was lowest in the fifth wave (7%). The average Ventilators
207 Utilization Ratio shows that all available ventilators were not fully utilized in any of the five
208 waves. The highest ratio was in wave 3 (20%) and the lowest ratio was in wave 5 (5%).
209 These two ratios suggest that most critical patients were put on oxygen for recovery and
210 a small proportion of these people were transferred to ventilators.

211 Deaths from COVID-19 were the highest during the third wave at 9,423, which also saw
212 the highest daily number of deaths (78.5) and the highest rate of increase in daily deaths.
213 Average daily deaths to hospitalization peaked during the second wave, while deaths to
214 ventilator use was the highest during the first. Average death to case ratio was the highest

215 for the third wave but was in the 2.2-2.8% range, with the exception of the fifth wave when
 216 it was 1.1%.

217 Pakistan’s vaccination drive started towards the end of wave 2, but full vaccination (i.e.,
 218 people receiving both their doses) did not occur until the beginning of wave 3.
 219 Consequently, total and daily new second dose of vaccine administered was highest in
 220 wave 5. Government restrictions, measured by the Oxford Health and Containment Index,
 221 appear to have been comparable in each wave.

222 Regression results

223 The results indicate the daily new COVID-19 cases were a statistically significant
 224 determinant for daily new deaths in all five waves at 95% CI; a one-percentage increase
 225 in COVID-19 cases caused a 0.46- 0.69 % increase in deaths across the five waves
 226 (Table 3).

227 **Table 3. Ordinary least squares (OLS) regression results for COVID-19 deaths**

LOG (Daily New COVID-19 Deaths)	(1) Wave 1	(2) Wave 2	(3) Wave 3	(4) Wave 4	(5) Wave 5
LOG (Daily New COVID-19 Cases) – 21-day delay	0.455* [0.289,0.620]	0.685* [0.430,0.939]	0.691* [0.358,1.025]	0.677* [0.542,0.812]	0.506* [0.189,0.823]
LOG (Daily New COVID-19 Tests) – 28-day delay	0.648* [0.260,1.037]	0.308 [-0.179,0.795]	-0.162 [-0.645,0.322]	0.268 [-0.122,0.657]	0.296 [-0.771,1.364]
Oxford Containment and Health Index – 14-day delay	-0.027* [-0.050, -0.005]	-0.009 [-0.030,0.012]	0.012 [-0.005,0.028]	0.017 [-0.006,0.040]	-0.030 [-0.072,0.013]
Time	-0.035* [-0.042, -0.028]	-0.002 [-0.005,0.001]	-0.009* [-0.016, -0.002]	-0.005* [-0.010, -0.000]	0.011 [-0.008,0.030]
Ventilator-Admitted Ratio	-16.662* [-29.406, -3.918]	0.555 [-10.098,11.208]	-11.074 [-25.332,3.183]	-14.092* [-19.096, -9.089]	-15.681* [-27.872, -3.489]

Oxygen-Admitted Ratio	3.734* [0.788,6.680]	4.413* [1.848,6.979]	0.148 [-5.421,5.718]	0.640 [-2.558,3.838]	2.435 [-4.943,9.814]
LOG (Second doses administered) 14-day delay	-	-	0.073* [0.006,0.139]	0.104* [0.010,0.198]	-0.375* [-0.668, -0.083]
Constant	-1.222 [-4.180,1.736]	-6.707* [-10.447, -2.967]	3.169 [-1.606,7.945]	-3.417 [-8.348,1.514]	-4.846 [-18.956,9.263]
Observations	122	128	104	147	83

228 **Significant at a 95% CI or higher*
 229 *Newey West CI in parentheses*
 230

231 The daily new COVID-19 tests and Oxford Health and Containment Index, which records
 232 the presence of government NPIs and restrictions, were both found to be a statistically
 233 significant determinants of COVID-19 deaths in wave 1. Increasing daily new tests by 1%
 234 will reduce the daily deaths by 0.65% (95% CI: 0.26%, 1.04%). While increase in Oxford
 235 Health and Containment Index by 1 point will result in 0.03% reduction in daily new deaths
 236 (95% CI: -0.05%, -0.005%).

237 The time trend variable is statistically significant in wave 1, wave 3 and wave 4. The
 238 coefficients indicate that, on average, daily COVID-19 deaths decreased at a rate of
 239 0.04% per day (95% CI: -0.04%, -0.03%) as time passed during wave 1. However, daily
 240 new deaths reduced at a rate of 0.01% per day during wave 3 (95% CI: -0.02%, 0.002%)
 241 and wave 4 (95% CI: -0.01%, 0.00%).

242 The ventilator to admitted ratio was statistically significant in wave 1, wave 4 and wave 5.
 243 The coefficient remains negative throughout these three waves and significant at 95% CI.
 244 The coefficients indicates that if ratio of patients on ventilator out of the admitted increases
 245 than daily new deaths decrease by 14-17%.

246 Oxygen to admitted ratio is only significant in wave 1 and 2 at 95% CI, where the
247 coefficient is positive. It means that if the ratio of oxygenated patient out of the total
248 admitted increase than daily new deaths due to COVID-19 will increase by approximately
249 4%.

250 Lastly, the number of fully vaccinated people came out to be statistically significant in
251 each of the last three waves. During wave 3, COVID-19 deaths increase by 0.07% (95%
252 CI: 0.006,0.14) as percentage of fully vaccinated people increase by one addition
253 percentage. This rate increased to 0.10% (95% CI: 0.006,0.14) during the wave 4.
254 However, in the fifth wave, daily new deaths due to COVID-19 decrease by 0.38% (95%
255 CI: -0.67, -0.08) as fully vaccinated people increases.

256 **DISCUSSION**

257 Pakistan experienced 5 distinct waves from 3rd April 2020 to 23rd February 2022. Our
258 analysis reflects both the evolution of Pakistan's response, as well as the differential
259 impact of different variants of the virus shaped the contours and features of each wave.
260 Pakistan experienced its initial wave earlier than other South Asian countries including
261 India, Bangladesh, Sri Lanka and Nepal, while peaks for the subsequent waves coincided
262 with those in other countries (31).

263 The upslope, as seen by the rate of change for testing and cases, was always steeper
264 than during the downward slope of a wave. This pattern follows what is known about
265 infectious epidemics in that cases rise quickly, plateau and then fall, slowly to an endemic
266 state where a low ebb of infections persist in the community in definitely (12). In fact, each
267 wave behaved as a typical epidemic caused by a distinct variant of the virus. Wave 1 was

268 dominated by B.1 variant, wave 2 by B.1.36 variant, the wave 3 by Alpha/B1.1.7 and
269 Delta/B.1.617.2 variants, wave 4 had majority cases of the Delta/B.1.617.2 variant (28–
270 30) while wave 5 was driven by Omicron/BA.5.2.1.7 (4).

271 A key challenge faced by Pakistan at the beginning of the pandemic was that there was
272 little prior experience with any pandemic outbreak of such level. Although disease
273 surveillance systems exist, they had not been scaled to manage case surveillance,
274 hospital admissions, daily deaths, and eventually large-scale adult vaccination and event
275 tracking. Pakistan has a federal system of governance where provinces provide health
276 services while the federal ministry provides guidance and coordination. In addition,
277 considerable curative care is in the private sector. To address the potential difficulties in
278 mounting a unified national response to the disease in the face of this diversity, a National
279 Action Plan for COVID-19 was formulated in March 2020 that placed the responsibility for
280 the national response in a National Coordination Committee (NCC) that was headed by
281 the Prime Minister and attended by all federal ministers. The NCC set national policy
282 which was implemented by the National Command and Operation Centre (NCOC) that
283 was co-headed by the military and civilian leadership (32). The NCOC coordinated the
284 management of the extensive lockdowns, other key NPIs such as school closures, limited
285 opening hours for essential businesses (examples of which included grocery stores and
286 pharmacies), closure of borders, cancellation of public events and social gatherings
287 (33,34). This was supported based on an elaborate data gathering and analysis system
288 that that guided daily decisions.

289 Wave 1 continued the longest and intervals became shorter between each successive
290 wave. Each wave showed unique features, that were determined by the particular variant

291 that drove that wave, along with the larger context that included the type of the variant
292 driving the wave, the extent and type of preventive interventions and eventually the
293 availability of the vaccine.

294 Pakistan's response to COVID-19 evolved over time. For example, Wave 1 had the
295 highest positivity rates and the longest duration, in part due to low initial rates of testing,
296 including very little contact tracing in the early days (35). As testing increased and mobility
297 restrictions tightened, duration of Waves 2 and 3 became shorter. However, by the end
298 of the second wave, intervention fatigue had set in. Implementation was laxer, and these
299 factors contributed to more cases and deaths of any wave during Wave 3. Indeed, the
300 Oxford Health and Containment Index was significant only during Wave 1 in terms of
301 preventing deaths.

302 In addition to preventive measures, the higher daily COVID-19 cases in waves 3, 4 and
303 5 may be attributed to highly transmissible Alpha (36,37), Delta (38,39) and Omicron (40)
304 variants, and to easing of severe restrictions such as lockdowns and school closures (41).
305 It is also possible that many cases were missed during Wave 1 due to limited testing.
306 However, the stability of daily testing in waves 3 to 5 suggests a stable equilibrium
307 between the testing system and how cases were being incident – the system was
308 capturing most of the cases from previously recognized populations and locations. It is
309 likely that undiagnosed cases and deaths were few, since as part of the national
310 surveillance, teams kept abreast of burials in large and mid-sized towns and also
311 periodically canvassed opinion of general practitioners about upsurges in respiratory
312 illnesses. On average, Pakistan had fewer cases per million population than neighboring

313 countries of India, Bangladesh, and Iran, as well as several of the developed countries
314 (31).

315 As with prevention, clinical management of cases evolved over time. Initially most cases
316 were hospitalized as seen by the high case to hospitalization ratio – only 27% of
317 admissions required oxygen 7% required ventilators during the Wave 1. In fact, there was
318 a correlation between deaths and oxygenation (which was mostly at hospitals) during
319 waves 1 and 2, a pattern that was seen globally. However, with each succeeding wave,
320 use of oxygen increased while ventilators fluctuated within a narrow range, as was also
321 seen in India (52,53). Thus, even as COVID-19 hospitalizations peaked during Wave 3,
322 hospitalization to case ratio increased, and average duration of hospitalization and the
323 use of hospitals for simple oxygenation fell, suggesting hospitals, ICU and ventilators,
324 were increasingly reserved only for the sickest (42). Deaths correlated best with a 21-day
325 delay model rather than a 28-day one, suggesting that most deaths happened early after
326 infection. Higher hospitalizations during the third wave may also have been attributed to
327 the Alpha followed by Delta variants (43–45). By contrast the lower hospitalizations,
328 length of stay and mortality during the fifth wave may be attributed to the Omicron variant
329 that was seen worldwide (46,47), and specifically in South Africa (48) and Brazil (49)
330 during the Omicron waves. Vaccination started halfway during wave 3 and more than half
331 of the eligible population was fully vaccinated (3) by the fifth wave, and may have
332 contributed to lower hospitalizations in Wave 5. Unlike COVID-19 induced major
333 challenges to the healthcare capacity in various countries (50,51), Pakistan was able to
334 build healthcare resources capacity to keep pace with the pandemic. Ventilator and
335 oxygen utilization never exceeded 20% and 24% respectively in wave 3.

336 Vaccination drive started in Pakistan by the end of February 2021. Despite a slow start,
337 vaccination picked up pace from 26,356 daily vaccinations in Wave 3 to 308,129 in the
338 fourth wave as it was rolled-out to younger population and vaccine supply increased in
339 the country. Average daily deaths did not reduce significantly due to vaccinations during
340 the third and fourth waves (56,57) but showed marked reduction in hospitalizations and
341 deaths towards the end of fourth and during the entire fifth wave (58).

342 From our regression model, we found that daily new COVID-19 cases were statistically
343 significant determinants of daily new deaths due to COVID-19. The association was also
344 observed from the third wave as both cumulative cases and deaths were the highest,
345 including the average daily deaths which were considerably higher than any other wave,
346 as seen in other countries (54). Secondly, daily new deaths due to COVID-19 increased
347 with patients on oxygenated beds while decreased with patients on ventilators in the initial
348 waves, potentially due to high patients load in hospitals, critical patients were put on
349 oxygen rather than ventilator. Fifth wave experienced the smallest number of daily
350 COVID-19 deaths possibly because it was dominated by the Omicron variant (55).

351 **LIMITATIONS**

352 There are a number of limitations associated with the data used in this paper. While the
353 official data used for the analysis are disaggregated by sub-national level, demographic
354 disaggregation, such as age or gender, are not available. This limits the analysis in terms
355 of the implication of gender and age on COVID-19 deaths. The national data is compiled
356 by aggregating the numbers for each subnational unit in Pakistan. However, such an
357 analysis would be too extensive to depict and therefore our analysis does not account for
358 sub-national differences. It is possible that distinctive cultures, behaviors and differences

359 in the stringency in enforcement of interventions vary between for regions and may in
360 theory, influence the number of COVID-19 cases and deaths.

361 Similarly, data for hospitalizations is also unaccompanied by any information on
362 comorbidities, as this information was not available beyond treating hospitals, losing a
363 level of richness of analysis that includes such comorbidities. Also, data for daily new
364 hospital admissions started becoming available towards the very end of wave 1.
365 Consequently, the average length of hospital stay could not be calculated for this wave.

366 The official vaccination data available to us at the time of this analysis is not desegregated
367 by the different types of available vaccines, for example Sinopharm, CanSino, Sputnik V
368 and others. Differential impact of each vaccine on COVID-19 deaths in Pakistan would
369 be informative. All of the above limitations notwithstanding, we are confident that this
370 study provides crucial insights into the prevailing trends of COVID-19 in Pakistan in
371 manner that is constructive.

372 **CONCLUSION**

373 COVID-19 management in Pakistan kept pace with the spread of the disease during five
374 distinct waves. We describe how these waves differed in terms of cases, hospitalizations
375 and deaths and analyze potential reasons for these differences. These lessons, as well
376 as limitations of our approach, provide important lessons for managing future pandemics.

377 **REFERENCES**

- 378 1. Noreen N, Dil S, Ullah S, Niazi K, Naveed I, Khan NU, et al. Coronavirus disease
379 (COVID-19) Pandemic and Pakistan; Limitations and Gaps. Limitations Gaps
380 Glob Biosecurity [Internet]. 2020;1(3). Available from:
381 <https://jglobalbiosecurity.com/articles/63/galley/170/download/>

- 382 2. Babu GR, Khetrpal S, John DA, Deepa R, Narayan KMV. Pandemic
383 preparedness and response to COVID-19 in South Asian countries. *Int J Infect*
384 *Dis* [Internet]. 2021;104:169–74. Available from:
385 <https://doi.org/10.1016/j.ijid.2020.12.048>
- 386 3. NCOC. Vaccine Statistics [Internet]. 2022 [cited 2022 Feb 23]. p. NCOC Official
387 Website. Available from: <https://covid.gov.pk/vaccine-details>
- 388 4. Badar N, Ikram A, Salman M, Umair M, Rehman Z, Ahad A, et al. Genomic
389 characterization of SARS-CoV-2 from Islamabad, Pakistan by Rapid Nanopore
390 sequencing. Available from: <https://doi.org/10.1101/2022.02.17.480826>
- 391 5. Coccia M. The impact of first and second wave of the COVID-19 pandemic in
392 society: comparative analysis to support control measures to cope with negative
393 effects of future infectious diseases. *Environ Res* [Internet].
394 2021;197(April):111099. Available from:
395 <https://doi.org/10.1016/j.envres.2021.111099>
- 396 6. Salyer SJ, Maeda J, Sembuche S, Kebede Y, Tshangela A, Moussif M, et al. The
397 first and second waves of the COVID-19 pandemic in Africa: a cross-sectional
398 study. *Lancet* [Internet]. 2021;397(10281):1265–75. Available from:
399 [http://dx.doi.org/10.1016/S0140-6736\(21\)00632-2](http://dx.doi.org/10.1016/S0140-6736(21)00632-2)
- 400 7. Iftimie S, Lopez-Azcona AF, Vallverdu I, Hernandez-Flix S, De Febrer G, Parra S,
401 et al. First and second waves of coronavirus disease-19: A comparative study in
402 hospitalized patients in Reus, Spain. *PLoS One*. 2021;16(3 March 2021):1–13.
- 403 8. Jalali SF, Ghassemzadeh M, Mouodi S, Javanian M, Kani MA, Ghadimi R, et al.
404 Epidemiologic comparison of the first and second waves of coronavirus disease in
405 Babol, North of Iran. *Casp J Intern Med*. 2020;11(2):S544–50.
- 406 9. Wouters OJ, Shadlen KC, Salcher-Konrad M, Pollard AJ, Larson HJ,
407 Teerawattananon Y, et al. Challenges in ensuring global access to COVID-19
408 vaccines: production, affordability, allocation, and deployment. *Lancet*. 2021 Mar
409 13;397(10278):1023–34.
- 410 10. Vanthomme K, Gadeyne S, Lusyne P, Vandenheede H. A population-based study
411 on mortality among Belgian immigrants during the first COVID-19 wave in
412 Belgium. Can demographic and socioeconomic indicators explain differential
413 mortality? *SSM - Popul Heal* [Internet]. 2021;14:100797. Available from:
414 <https://doi.org/10.1016/j.ssmph.2021.100797>
- 415 11. So MKP, Chu AMY, Tiwari A, Chan JNL. On topological properties of COVID-19:
416 predicting and assessing pandemic risk with network statistics. *Sci Rep* [Internet].
417 2021;11(1):1–14. Available from: <https://doi.org/10.1038/s41598-021-84094-z>
- 418 12. Wasserheit JN, Aral SO. The dynamic topology of sexually transmitted disease
419 epidemics: Implications for prevention strategies. *J Infect Dis*. 1996;174(SUPPL.
420 2).
- 421 13. Sibiri H, Prah D, Zankawah SM. Containing the impact of COVID-19: Review of

- 422 Ghana's response approach. *Heal Policy Technol* [Internet]. 2021;10(1):13–5.
423 Available from: <https://doi.org/10.1016/j.hlpt.2020.10.015>
- 424 14. Olufadewa II, Adesina MA, Ekpo MD, Akinloye SJ, Iyanda TO, Nwachukwu P, et
425 al. Lessons from the coronavirus disease 2019 (COVID-19) pandemic response in
426 China, Italy, and the U.S.: a guide for Africa and low- and middle-income
427 countries. *Glob Heal J* [Internet]. 2021;5(1):56–61. Available from:
428 <https://doi.org/10.1016/j.glohj.2021.02.003>
- 429 15. He D, Zhao S, Xu X, Lin Q, Zhuang Z, Cao P, et al. Low dispersion in
430 the infectiousness of COVID-19 cases implies difficulty in control. *BMC Public*
431 *Health*. 2020;20(1):2–5.
- 432 16. Van Nguyen Q, Cao DA, Nghiem SH. Spread of COVID-19 and policy responses
433 in Vietnam: An overview. *Int J Infect Dis* [Internet]. 2021;103:157–61. Available
434 from: <https://doi.org/10.1016/j.ijid.2020.11.154>
- 435 17. Sharma A, Borah SB, Moses AC. Responses to COVID-19: The role of
436 governance, healthcare infrastructure, and learning from past pandemics. *J Bus*
437 *Res* [Internet]. 2021;122(102):597–607. Available from:
438 <https://doi.org/10.1016/j.jbusres.2020.09.011>
- 439 18. Seong H, Hyun HJ, Yun JG, Noh JY, Cheong HJ, Kim WJ, et al. Comparison of
440 the second and third waves of the COVID-19 pandemic in South Korea:
441 Importance of early public health intervention. *Int J Infect Dis* [Internet].
442 2021;104:742–5. Available from: <https://doi.org/10.1016/j.ijid.2021.02.004>
- 443 19. OxCGRT. OxCGRT COVID Policy Tracker Data [Internet]. 2021. Available from:
444 <https://github.com/OxCGRT/covid-policy-tracker/tree/master/data/timeseries>
- 445 20. Hale T, Anania J, Angrist N, Bobby T, Cameron-Blake E, Falco M Di, et al.
446 Variation in government responses to COVID-19, Version 12.0 [Internet]. BSG
447 Working Paper Series. 2021. Available from:
448 <https://covidtracker.bsg.ox.ac.uk/stringency-scatter>
- 449 21. Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real estimates of
450 mortality following COVID-19 infection. *Lancet Infect Dis* [Internet].
451 2020;20(7):773. Available from: [http://dx.doi.org/10.1016/S1473-3099\(20\)30195-X](http://dx.doi.org/10.1016/S1473-3099(20)30195-X)
- 452 22. Elezkurtaj S, Greuel S, Ihlow J, Michaelis EG, Bischoff P, Kunze CA, et al.
453 Causes of death and comorbidities in hospitalized patients with COVID-19. *Sci*
454 *Rep* [Internet]. 2021;11(1):1–9. Available from: <https://doi.org/10.1038/s41598-021-82862-5>
455
- 456 23. Marschner IC. Estimating age-specific COVID-19 fatality risk and time to death by
457 comparing population diagnosis and death patterns: Australian data. *BMC Med*
458 *Res Methodol* [Internet]. 2021;21(1):1–10. Available from:
459 <https://doi.org/10.1186/s12874-021-01314-w>
- 460 24. Asirvatham ES, Sarman CJ, Saravanamurthy SP, Mahalingam P,
461 Maduraipandian S, Lakshmanan J. Who is dying from COVID-19 and when? An

- 462 Analysis of fatalities in Tamil Nadu, India. *Clin Epidemiol Glob Heal* [Internet].
463 2021;9:275–9. Available from:
464 <https://www.sciencedirect.com/science/article/pii/S2213398420302189>
- 465 25. Borobia AM, Carcas AJ, Pérez-Olmeda M, Castaño L, Bertran MJ, García-Pérez
466 J, et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-
467 primed participants (CombiVacS): a multicentre, open-label, randomised,
468 controlled, phase 2 trial. *Lancet*. 2021;398(10295):121–30.
- 469 26. Li J, Hou L, Guo X, Jin P, Wu S, Zhu J, et al. Heterologous prime-boost
470 immunization with CoronaVac and Convidecia. *medRxiv* [Internet].
471 2021;(20):2021.09.03.21263062. Available from:
472 <http://medrxiv.org/content/early/2021/09/06/2021.09.03.21263062.abstract>
- 473 27. Liu X, Shaw RH, Stuart AS, Greenland M, Dinesh T, Provstgaard-Morys S, et al.
474 Safety and Immunogenicity Report from the Com-COV Study – a Single-Blind
475 Randomised Non-
476 Inferiority Trial Comparing Heterologous And
477 Homologous Prime-Boost Schedules with An Adenoviral Vected and
478 mRNA COVID-19 Vaccine. *SSRN Electronic Journal*. 2021.
- 479 28. Umair M, Ikram A, Rehman Z, Haider A, Badar N, Ammar M, et al. Genomic
480 diversity of SARS-CoV-2 in Pakistan during fourth wave of pandemic. *medRxiv*
481 [Internet]. 2021;92(51):2021.09.30.21264343. Available from:
482 <http://medrxiv.org/content/early/2021/10/03/2021.09.30.21264343.abstract>
- 483 29. Basheer A, Zahoor I. Genomic epidemiology of SARS-CoV-2 divulge B.1, B.1.36,
484 and B.1.1.7 as the most dominant lineages in first, second, and third wave of
485 SARS-CoV-2 infections in Pakistan. *Microorganisms* [Internet]. 2021 [cited 2022
486 Sep 21];9(12). Available from: <https://doi.org/10.3390/microorganisms9122609>
- 487 30. Shakeel M, Irfan M, Nisa Z un, Farooq S, Ain N ul, Iqbal W, et al. Genome
488 sequencing and analysis of genomic diversity in the locally transmitted SARS-
489 CoV-2 in Pakistan. *Transbound Emerg Dis* [Internet]. 2022; Available from:
490 <http://tree.bio.ed.ac.uk/software/fig.tree/>
- 491 31. Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, et al.
492 Coronavirus Pandemic (COVID-19) [Internet]. *OurWorldInData.org*. 2020.
493 Available from: <https://ourworldindata.org/coronavirus>
- 494 32. National Institute of Health Pakistan. National Action Plan for Corona virus
495 disease (COVID-19) Pakistan [Internet]. 2020. Available from:
496 [https://www.nih.org.pk/wp-content/uploads/2020/03/COVID-19-NAP-V2-13-
497 March-2020.pdf](https://www.nih.org.pk/wp-content/uploads/2020/03/COVID-19-NAP-V2-13-March-2020.pdf)
- 498 33. Gul A. Pakistan Seals Borders, Shuts Schools, Bans Public Events Over
499 Coronavirus. *Voanews.com* [Internet]. 2020 Mar 13;COVID-19 Pandemic.
500 Available from: [https://www.voanews.com/a/science-health_ coronavirus-
501 outbreak_pakistan-seals-borders-shuts-schools-bans-public-events-
502 over/6185785.html](https://www.voanews.com/a/science-health_coronavirus-outbreak_pakistan-seals-borders-shuts-schools-bans-public-events-over/6185785.html)

- 503 34. Chandir S, Siddiqi DA, Setayesh H, Khan AJ. Impact of COVID-19 lockdown on
504 routine immunisation in Karachi, Pakistan. *Lancet Glob Heal* [Internet].
505 2020;8(9):e1118–20. Available from:
506 [https://www.thelancet.com/journals/langlo/article/PIIS2214-109X\(20\)30290-](https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(20)30290-4/fulltext)
507 [4/fulltext](https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(20)30290-4/fulltext)
- 508 35. Habib M, Abbas M. Facing the Threat of COVID-19 in Pakistan: A Nation's
509 Dilemma. *Value Heal Reg issues*. 2021 May;24:90–5.
- 510 36. Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Assessing
511 transmissibility of SARS-CoV-2 lineage B.1.1.7 in England The COVID-19
512 Genomics UK (COG-UK) consortium. *Nature* [Internet]. 2021;593. Available from:
513 <https://doi.org/10.1038/s41586-021-03470-x>
- 514 37. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al.
515 Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England.
516 *Science* (80-) [Internet]. 2021;372(6538). Available from:
517 <http://science.sciencemag.org/>
- 518 38. Zhan Y, Yin H, Yin J-Y. (Delta) Variant of SARS-CoV-2: features, transmission
519 and potential strategies. *Int J Biol Sci* [Internet]. 2022;2022(5):1844–51. Available
520 from: <https://www.ijbs.com//creativecommons.org/licenses/by/4.0/>
- 521 39. Kumar S, Tripathi V, Zhang J, Hu Z, Huang X, Fu S, et al. Differences in Clinical
522 Characteristics Between Delta Variant and Wild-Type SARS-CoV-2 Infected
523 Patients. *Front Med | www.frontiersin.org* [Internet]. 2019;1:792135. Available
524 from: www.frontiersin.org
- 525 40. Tian D, Sun Y, Xu H, Ye Q. The emergence and epidemic characteristics of the
526 highly mutated SARS-CoV-2 Omicron variant. 2022; Available from:
527 <https://www.gisaid.org/>
- 528 41. Provinces announce easing lockdown even as Pakistan witnesses record rise in
529 coronavirus cases [Internet]. *DAWN*. 2020 [cited 2022 Aug 1]. Available from:
530 <https://www.dawn.com/news/1555575>
- 531 42. Karagiannidis C, Windisch W, McAuley DF, Welte T, Busse R. Major differences
532 in ICU admissions during the first and second COVID-19 wave in Germany
533 [Internet]. Vol. 9, *The Lancet Respiratory Medicine*. 2021 [cited 2022 Oct 7]. p.
534 e47–8. Available from: <https://doi.org/>
- 535 43. Twohig KA, Nyberg T, Zaidi A, Thelwall S, Sinnathamby MA, Aliabadi S, et al.
536 Hospital admission and emergency care attendance risk for SARS-CoV-2 delta
537 (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study.
538 *Lancet Infect Dis* [Internet]. 2021; Available from:
539 [https://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(21\)00475-](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00475-8/fulltext)
540 [8/fulltext](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00475-8/fulltext)
- 541 44. Shiehzadegan S, Alaghemand N, Fox M, Venketaraman V. Analysis of the Delta
542 Variant B.1.617.2 COVID-19. *Clin Pr* [Internet]. 2021;11:778–84. Available from:
543 <https://doi.org/10.3390/clinpract11040093>

- 544 45. Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in
545 Scotland: demographics, risk of hospital admission, and vaccine effectiveness.
546 Lancet [Internet]. 2021 Jun 26 [cited 2022 Oct 7];397(10293):2461–2. Available
547 from: <http://www.thelancet.com/article/S0140673621013581/fulltext>
- 548 46. Chenchula S, Karunakaran P, Sharma S, Chavan M. Current evidence on efficacy
549 of COVID-19 booster dose vaccination against the Omicron variant: A systematic
550 review. J Med Virol [Internet]. 2022 Jul 1 [cited 2022 Oct 7];94(7):2969–76.
551 Available from: <https://pubmed.ncbi.nlm.nih.gov/35246846/>
- 552 47. Ulloa AC, Buchan SA, Daneman N, Brown KA. Estimates of SARS-CoV-2
553 Omicron Variant Severity in Ontario, Canada. JAMA [Internet]. 2022 Apr 5 [cited
554 2022 Oct 7];327(13):1286–8. Available from:
555 <https://jamanetwork.com/journals/jama/fullarticle/2789408>
- 556 48. Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B.
557 Characteristics and Outcomes of Hospitalized Patients in South Africa during the
558 COVID-19 Omicron wave Compared with Previous waves. JAMA - J Am Med
559 Assoc. 2022 Feb 8;327(6):583–4.
- 560 49. Martins-Filho PR, de Souza Araújo AA, Quintans-Júnior LJ, Soares BDS, Barboza
561 W de S, Cavalcante TF, et al. Dynamics of hospitalizations and in-hospital deaths
562 from COVID-19 in northeast Brazil: a retrospective analysis based on the
563 circulation of SARS-CoV-2 variants and vaccination coverage. Epidemiol Health
564 [Internet]. 2022 [cited 2022 Oct 7];44:e2022036. Available from:
565 <https://pubmed.ncbi.nlm.nih.gov/35413166/>
- 566 50. Mateen BA, Wilde H, Dennis JM, Duncan A, Thomas N, McGovern A, et al.
567 Hospital bed capacity and usage across secondary healthcare providers in
568 England during the first wave of the COVID-19 pandemic: a descriptive analysis.
569 BMJ Open [Internet]. 2021 Jan 26 [cited 2022 Oct 7];11(1). Available from:
570 <https://pubmed.ncbi.nlm.nih.gov/33500288/>
- 571 51. Mahendradhata Y, Andayani NLPE, Hasri ET, Arifi MD, Siahaan RGM, Solikha
572 DA, et al. The Capacity of the Indonesian Healthcare System to Respond to
573 COVID-19. Front Public Heal. 2021 Jul 7;9:887.
- 574 52. Kumar G, Mukherjee A, Sharma RK, Menon GR, Sahu D, Wig N, et al. Clinical
575 profile of hospitalized COVID-19 patients in first & second wave of the pandemic:
576 Insights from an Indian registry based observational study. Indian J Med Res
577 [Internet]. 2021 May 1 [cited 2022 Oct 7];153(5–6):619. Available from:
578 </pmc/articles/PMC8555588/>
- 579 53. Budhiraja S, Indrayan A, Aggarwal M, Jha V, Jain D, Tarai B, et al. Differentials in
580 the characteristics of COVID-19 cases in wave-1 and wave-2 admitted to a
581 network of hospitals in North India [Preprint]. medRxiv [Internet]. 2021 Jun 27
582 [cited 2022 Oct 7];2021.06.24.21259438. Available from:
583 <https://www.medrxiv.org/content/10.1101/2021.06.24.21259438v1>
- 584 54. Anscombe C, Lissauer S, Thole H, Rylance J, Dula D, Menyere M, et al. A

- 585 comparison of four epidemic waves of COVID-19 in Malawi; an observational
586 cohort study [Preprint]. medRxiv [Internet]. 2022 [cited 2022 Oct 7]; Available
587 from: [/pmc/articles/PMC9298135/](https://pubmed.ncbi.nlm.nih.gov/34971823/)
- 588 55. Abdullah F, Myers J, Basu D, Tintinger G, Ueckermann V, Mathebula M, et al.
589 Decreased severity of disease during the first global omicron variant covid-19
590 outbreak in a large hospital in tshwane, south africa. Int J Infect Dis [Internet].
591 2022 Mar 1 [cited 2022 Oct 7];116:38–42. Available from:
592 <https://pubmed.ncbi.nlm.nih.gov/34971823/>
- 593 56. Jabłońska K, Aballéa S, Toumi M. The real-life impact of vaccination on COVID-
594 19 mortality in Europe and Israel. Public Health. 2021 Sep 1;198(May):230–7.
- 595 57. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al.
596 Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl
597 J Med [Internet]. 2021 Aug 12 [cited 2022 Oct 7];385(7):585–94. Available from:
598 <https://pubmed.ncbi.nlm.nih.gov/34289274/>
- 599 58. Xavier CR, Oliveira RS, Vieira V da F, Lobosco M, Dos Santos RW.
600 Characterisation of Omicron Variant during COVID-19 Pandemic and the Impact
601 of Vaccination, Transmission Rate, Mortality, and Reinfection in South Africa,
602 Germany, and Brazil. BioTech [Internet]. 2022 Jun 1 [cited 2022 Oct 7];11(2).
603 Available from: [/pmc/articles/PMC9264399/](https://pubmed.ncbi.nlm.nih.gov/34289274/)

604

605 **List of Legends**


606 **Table 1. Augmented Dicky-Fuller tests for unit roots**

607 **Table 2. Descriptive characteristics of each COVID-19 wave**

608 **Table 3. Ordinary least squares (OLS) regression results for COVID-19 deaths**

609 **Figure 1. COVID-19 waves and daily new cases**

610 **S1 Table. Calculated ratio variables and their descriptions**



Figure